Cite
HARVARD Citation
Landmesser, U. et al. (2017). European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. European heart journal. pp. 2245-2255. [Online].